Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113679 · ClinicalTrials.gov registry record · NA
Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting
A NA study, sponsored by EmitBio.
- Terminated
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT06113679 is a NA study that was terminated before completion, run by EmitBio. The registered enrollment target is 41 participants.
The verdict
NCT06113679, a NA study, was terminated before completion, sponsored by EmitBio.
- TERMINATED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day 36, (+3/-3days). Subjects will receive a weekly televisit during Week 3 / day 15 (+3/-3), Week 4 / day 22 (+3/-3), and Week 5 / day 29 (+3/-3).
Interventions
- DEVICE RDX-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2024-06-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06113679
The ClinicalTrials.gov registry entry for NCT06113679 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EmitBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RDX-19 is the first listed.
NCT06113679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06113679 about?
NCT06113679 is a clinical study titled "Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting". Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day 36...
What is the current status of trial NCT06113679?
This trial is currently terminated. It is a NA study. The enrollment target is 41 participants. The study started on 2023-10-30. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT06113679?
The interventions under investigation include: RDX-19 (DEVICE).
Who is sponsoring clinical trial NCT06113679?
This trial is sponsored by EmitBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.